|
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer Clinical research trials and Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer. Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer clinical trial. Participants frequently obtain the most expert healthcare available for their Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
For Condition: Carcinoma, Non-Small-Cell Lung
Status: No longer recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: Taxol and carboplatin are commonly used drugs for the treatment of stage IIIB or IV non small cell lung carcinoma. This study compares treatment with Taxol/carboplatin given every 3 weeks to a schedule where it is given weekly. The purpose of the study is to determine the most effective and safe schedule for giving these drugs in non small cell lung carcinoma.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - Confirmation of non-small cell bronchogenic carcinoma (epidermoid, squamous, adeno, large cell anaplastic carcinoma, but no small cell or carcinoid) must be histologically or cytologically confirmed. - No prior antineoplastic chemotherapy, hormonal therapy or therapy with biological response modifiers - No previous irradiation to the only area of measurable disease. Exclusion Criteria: - Past or current history of neoplasm other than the entry diagnosis. Exceptions are curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix or other cancers treated by surgery or radiation with a disease free survival longer than 5 years. - Patients who have undergone surgery less than 3 weeks prior to enrollment. - History of serious cardiac disease not adequately controlled. - Patients with serious active infections or other serious underlying medical condition. - Uncontrolled diabetes mellitis.
Total Enrollment: 444
Location and Contact Information:
West Suburban Center for Cancer Care
River Forest, Illinois, 60305
United States
Mid Illinois Hematology and Oncology Associates, Ltd.
Normal, Illinois, 61761
United States
Fairview-University Medical Center, University of Minnesota
Minneapolis, Minnesota, 55455
United States
Wellstar Cobb Hospital
Austell, Georgia, 30060
United States
Mercy Cancer Center
Mason City, Iowa, 50401
United States
Good Samaritan Medical Center
West Palm Beach, Florida, 33401
United States
Don & Sybil Harrington Cancer Center
Amarillo, Texas, 79106
United States
Little Rock Hematology/Oncology Associates
Little Rock, Arkansas, 72205
United States
Mid Dakota Clinic
Bismark, North Dakota, 58501
United States
Danbury Hospital/Praxair Cancer Center
Danbury, Connecticut, 06810
United States
Madigan Army Medical Center
Tacoma, Washington, 98431
United States
Metro Minnesota CCOP
St. Louis Park, Minnesota, 55416
United States
Associated Physicians & Surgeons Clinic, LLC
Terre Haute, Indiana, 47804
United States
Siouxland Hematology/Oncology Associates
Sioux City, Iowa, 51101
United States
Southwest Regional Cancer Center
Austin, Texas, 78705
United States
Hematology-Oncology of Central New Jersey
Red Bank, New Jersey, 07701
United States
Central Pennsylvania Hematology & Medical Oncology Associates, P.C.
Lemoyne, Pennsylvania, 17043
United States
Northwest Medical Specialties, PLLC
Tacoma, Washington, 98405
United States
Quadrangle Medical Specialists, Southern Oncology Research
Greenville, North Carolina, 27834
United States
Raleigh Hematology Associates, Wake Practice
Cary, North Carolina, 27609
United States
Naval Medical Center
San Diego, California, 92134
United States
Jewish Medical Plaza
Louisville, Kentucky, 40202
United States
The Center for Cancer and Hematologic Disease
Cherry Hill, New Jersey, 08003
United States
Brackenridge Hospital
Austin, Texas, 78701
United States
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109
United States
Maimonides Medical Center
Brooklyn, New York, 11209
United States
Boston Cancer Group, PLC
Memphis, Tennessee, 38104
United States
Clifton Springs Hospital and Clinic
Clifton Springs, New York, 14432
United States
Advanced Oncology Associates
Armonk, New York, 10504
United States
Ellis Fischel Cancer Center
Columbia, Missouri, 65203
United States
Upstate New York Cancer R & E
Rochester, New York, 14623
United States
Community Medical Center
Toms River, New Jersey, 08755
United States
Joliet Oncology/Hematology Associates,Ltd.
Joliet, Illinois, 60435
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
Columbus CCOP
Columbus, Ohio, 43206
United States
Hematology and Oncology Associates of Southern Michigan,P.C
Jackson, Michigan, 49201
United States
Washington VA Medical Center
Washington D.C., District of Columbia, 20422
United States
Community Cancer Care, Inc.
Indianapolis, Indiana, 46202
United States
Hematology/Oncology of Rockland
New York City, New York,
United States
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, 19141
United States
Genesis Cancer Center
Hot Springs, Arkansas, 71913
United States
University of Louisville
Louisville, Kentucky, 40202
United States
Walter Reed Army Hospital
Washington D.C., District of Columbia, 20307
United States
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
United States
Louisiana State University Health Sciences Center
Shreveport, Louisiana, 71130
United States
University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213
United States
Goshen Medical Associates
Goshen, New York, 10924
United States
New York Oncology-Hematology,P.C./Capital District Hematology, Oncology Associates
Latham, New York, 12110
United States
Southwest Cancer Center
Lubbock, Texas, 79415
United States
Guthrie Clinic Ltd
Sayre, Pennsylvania, 18840
United States
Brooklyn VA
Brooklyn, New York, 11209
United States
Maine General Medical Center
Waterville, Maine, 04901
United States
Medical Oncology Care Associates
Orange, California, 92868
United States
Highlands Oncology Group
Springdale, Arkansas, 72764
United States
Creighton University Cancer Center
Omaha, Nebraska, 68131
United States
Louisiana Oncology Associates
Lafayette, Louisiana, 70506
United States
Additional Information:
Study ID Numbers: BMS TAX/MEN.12;
Study Start Date: June 2000
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035152
Other Carcinoma, Non-Small-Cell Lung Studies:
1. ALIMTA plus Carboplatin as Front-Line Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
2. A Phase 3 Randomized Study of Lonafarnib in Combination With Paclitaxel and Carboplatin vs. Placebo in Combination with Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer
3. Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects with Non-Small Cell Lung Cancer (NSCLC)
4. Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)
5. Study of Cetuximab in Combination with Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer
Related Studies:
Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Arkansas Clinical Trials
Other Little Rock Clinical Trials
Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer
|
|
|
|
|
|
|
|